HIGHLIGHTS
- who: Perjeta. and collaborators from the National Medical University means of cost-effectiveness and cost-utility methods was carried outAs an have published the Article: УДК: 618.19-006.6-085 Pharmacoeconomic analysis of pertuzumab in treatment of HER2-positive, in the Journal: (JOURNAL)
- what: 1.
SUMMARY
Probability of passing through different Markov statuses in PTD and TD groups Стан, з якого здійснюється перехід FROM status Без прогресування No progression Прогресування Progression Оригінальні дослідження Без прогресування No progression PTD TD Стан, до якого здійснюється перехід TO status Прогресування Progression PTD TD PTD Смерть Death TD ISSN 2708-7166 (Print) ISSN 2708-7174 (Online) Рис. The cost-utility method makes it possible to . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.